pyrazinamide has been researched along with Extensively Drug-Resistant Tuberculosis in 27 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Extensively Drug-Resistant Tuberculosis: Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pyrazinamide (PZA) is an antibiotic used in first- and second-line tuberculosis treatment regimens." | 1.56 | Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid. ( Amzel, LM; Antiparra, R; Gilman, RH; Kirwan, DE; Lopez, JM; Maruenda, H; Saavedra, H; Sheen, P; Toscano, E; Vallejos-Sánchez, K; Zimic, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Khanna, A | 1 |
| Raj, VS | 1 |
| Tarai, B | 1 |
| Sood, R | 1 |
| Pareek, PK | 1 |
| Upadhyay, DJ | 1 |
| Sharma, P | 1 |
| Rattan, A | 1 |
| Saini, KS | 1 |
| Singh, H | 1 |
| Perveen, S | 1 |
| Kumari, D | 1 |
| Singh, K | 1 |
| Sharma, R | 1 |
| Cho, HJ | 1 |
| Lim, YJ | 1 |
| Kim, J | 1 |
| Koh, WJ | 1 |
| Song, CH | 1 |
| Kang, MW | 1 |
| Vallejos-Sánchez, K | 1 |
| Lopez, JM | 1 |
| Antiparra, R | 1 |
| Toscano, E | 1 |
| Saavedra, H | 1 |
| Kirwan, DE | 1 |
| Amzel, LM | 1 |
| Gilman, RH | 1 |
| Maruenda, H | 1 |
| Sheen, P | 1 |
| Zimic, M | 1 |
| Ghosh, A | 1 |
| N, S | 1 |
| Saha, S | 1 |
| Saroha, D | 1 |
| Garg, D | 1 |
| Singh, AK | 1 |
| Dhamija, RK | 1 |
| Ignatius, EH | 1 |
| Swindells, S | 1 |
| Kuo, CY | 1 |
| Wang, WH | 1 |
| Huang, CH | 1 |
| Chen, YH | 1 |
| Lu, PL | 1 |
| Ismail, NA | 1 |
| Mvusi, L | 1 |
| Nanoo, A | 1 |
| Dreyer, A | 1 |
| Omar, SV | 1 |
| Babatunde, S | 1 |
| Molebatsi, T | 1 |
| van der Walt, M | 1 |
| Adelekan, A | 1 |
| Deyde, V | 1 |
| Ihekweazu, C | 1 |
| Madhi, SA | 1 |
| O'Donnell, MR | 1 |
| Padayatchi, N | 1 |
| Kvasnovsky, C | 1 |
| Werner, L | 1 |
| Master, I | 1 |
| Horsburgh, CR | 1 |
| Alame-Emane, AK | 1 |
| Xu, P | 1 |
| Pierre-Audigier, C | 1 |
| Cadet-Daniel, V | 1 |
| Shen, X | 1 |
| Sraouia, M | 1 |
| Siawaya, JF | 1 |
| Takiff, H | 1 |
| Gao, Q | 1 |
| Gicquel, B | 1 |
| Rienthong, S | 1 |
| Boonin, C | 1 |
| Chaiyasirinrote, B | 1 |
| Satproedprai, N | 1 |
| Mahasirimongkol, S | 1 |
| Yoshida, H | 1 |
| Kondo, Y | 1 |
| Namwat, C | 1 |
| Rienthong, D | 1 |
| Maslov, DA | 1 |
| Zaĭchikova, MV | 1 |
| Chernousova, LN | 1 |
| Shur, KV | 1 |
| Bekker, OB | 1 |
| Smirnova, TG | 1 |
| Larionova, EE | 1 |
| Andreevskaya, SN | 1 |
| Zhang, Y | 2 |
| Danilenko, VN | 1 |
| Wolfson, LJ | 1 |
| Gibbert, J | 1 |
| Wirth, D | 1 |
| Diel, R | 1 |
| Günther, G | 1 |
| van Leth, F | 1 |
| Altet, N | 1 |
| Dedicoat, M | 1 |
| Duarte, R | 1 |
| Gualano, G | 1 |
| Kunst, H | 1 |
| Muylle, I | 1 |
| Spinu, V | 1 |
| Tiberi, S | 1 |
| Viiklepp, P | 1 |
| Lange, C | 1 |
| McNaughton, A | 1 |
| Blackmore, T | 1 |
| McNaughton, H | 1 |
| Dookie, N | 1 |
| Sturm, AW | 2 |
| Moodley, P | 3 |
| Fofana, MO | 1 |
| Shrestha, S | 1 |
| Knight, GM | 1 |
| Cohen, T | 1 |
| White, RG | 1 |
| Cobelens, F | 1 |
| Dowdy, DW | 1 |
| Allana, S | 1 |
| Shashkina, E | 2 |
| Mathema, B | 2 |
| Bablishvili, N | 1 |
| Tukvadze, N | 1 |
| Shah, NS | 2 |
| Kempker, RR | 1 |
| Blumberg, HM | 1 |
| Mlisana, K | 1 |
| Brust, JC | 1 |
| Gandhi, NR | 2 |
| Murray, S | 1 |
| Mendel, C | 1 |
| Spigelman, M | 1 |
| Calver, AD | 1 |
| Falmer, AA | 1 |
| Murray, M | 1 |
| Strauss, OJ | 1 |
| Streicher, EM | 1 |
| Hanekom, M | 1 |
| Liversage, T | 1 |
| Masibi, M | 1 |
| van Helden, PD | 2 |
| Warren, RM | 2 |
| Victor, TC | 1 |
| Hoek, KG | 1 |
| Schaaf, HS | 1 |
| Gey van Pittius, NC | 1 |
| Caminero, JA | 1 |
| Sotgiu, G | 1 |
| Zumla, A | 1 |
| Migliori, GB | 1 |
| Kim, HJ | 1 |
| Kwak, HK | 1 |
| Lee, J | 1 |
| Yun, YJ | 1 |
| Lee, JS | 1 |
| Lee, MS | 1 |
| Min, SY | 1 |
| Park, SK | 1 |
| Kang, HS | 1 |
| Maeng, YH | 1 |
| Kim, SY | 2 |
| Kook, YH | 1 |
| Kim, YR | 1 |
| Lee, KH | 1 |
| Wallis, RS | 1 |
| Jakubiec, W | 1 |
| Mitton-Fry, M | 1 |
| Ladutko, L | 1 |
| Campbell, S | 1 |
| Paige, D | 1 |
| Silvia, A | 1 |
| Miller, PF | 1 |
| Weissman, D | 1 |
| Ramathal, M | 1 |
| Elson, I | 1 |
| Kreiswirth, BN | 1 |
| Rothenberg, R | 1 |
| Moll, AP | 1 |
| Friedland, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy[NCT03941496] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2022-10-31 | Withdrawn (stopped due to The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pyrazinamide and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Res | 2022 |
Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.
Topics: Anti-HIV Agents; Antitubercular Agents; Drug Interactions; Extensively Drug-Resistant Tuberculosis; | 2020 |
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple; Ethambutol; Extensively Dru | 2010 |
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Ag | 2007 |
23 other studies available for pyrazinamide and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysi | 2010 |
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Cycloserine; Extensively Drug-Resistant Tuberculosis; Female; Humans; | 2020 |
Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Extensively Drug-Re | 2020 |
Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species.
Topics: Antitubercular Agents; Bacterial Proteins; Data Curation; Databases, Genetic; DNA, Bacterial; Drug R | 2020 |
Irreversible neuropathy in extremely-drug resistant tuberculosis: An unfortunate clinical conundrum.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Clofazimine; Cycloserine; Deprescriptions; Diaryl | 2020 |
Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
Topics: Aminosalicylic Acid; Antitubercular Agents; Ethambutol; Extensively Drug-Resistant Tuberculosis; Flu | 2018 |
Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cross-Sectional Studies; Extensively Drug-Res | 2018 |
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Therapy, Combination; Etham | 2013 |
Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance.
Topics: Amidohydrolases; Antitubercular Agents; China; DNA Mutational Analysis; DNA, Bacterial; Drug Resista | 2015 |
Evaluation of a novel line-probe assay for genotyping-based diagnosis of Mycobacterium tuberculosis in Thailand.
Topics: Antibiotics, Antitubercular; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Genotype; Hu | 2015 |
Resistance to pyrazinamide in Russian Mycobacterium tuberculosis isolates: pncA sequencing versus Bactec MGIT 960.
Topics: Amidohydrolases; Antitubercular Agents; Bacteriological Techniques; DNA Mutational Analysis; Drug Re | 2015 |
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
Topics: Antitubercular Agents; Computer Simulation; Cost-Benefit Analysis; Diarylquinolines; Drug Costs; Dru | 2015 |
Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.
Topics: Adult; Antitubercular Agents; Ethambutol; Ethionamide; Europe; Extensively Drug-Resistant Tuberculos | 2015 |
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand.
Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Cl | 2016 |
Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa.
Topics: Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Catalase; Drug Resistance, Multiple, Bac | 2016 |
A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Bayes Theorem; Biological Availability; Computer Simulation; Drug Administrat | 2017 |
pncA Gene Mutations Associated with Pyrazinamide Resistance in Drug-Resistant Tuberculosis, South Africa and Georgia.
Topics: Amidohydrolases; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resis | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Etham | 2016 |
Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa.
Topics: Adult; Antitubercular Agents; Communicable Diseases, Emerging; Contact Tracing; Directly Observed Th | 2010 |
Resistance to pyrazinamide and ethambutol compromises MDR/XDR-TB treatment.
Topics: Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combin | 2009 |
Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea.
Topics: Adult; Amidohydrolases; Antitubercular Agents; Bacterial Proteins; Base Sequence; DNA Mutational Ana | 2012 |
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Eth | 2012 |
Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa.
Topics: Adult; Antitubercular Agents; Cluster Analysis; Cross Infection; Drug Therapy, Combination; Ethambut | 2013 |